Related Experiment Video

Updated: Dec 12, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

998

A Review of Remdesivir for COVID-19: Data to Date

Monica Mehta1, Grace I Shyh

  • 1From the Department of Pharmacy, New York-Presbyterian Hospital, New York, NY.

Cardiology in Review
|August 11, 2020
PubMed

Insights

Remdesivir, an antiviral, is a potential therapy for severe acute respiratory coronavirus-2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19). This review covers its history, trials, and accessibility for hospitalized patients.

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, presents significant global health challenges.
  • Post-infection complications and severe outcomes necessitate effective therapeutic strategies.
  • Remdesivir has emerged as a key antiviral treatment option.

Purpose of the Study:

  • To provide a comprehensive overview of the antiviral drug remdesivir.
  • To discuss its historical development, pharmacological properties, and clinical trial data.
  • To address adverse events and accessibility concerns related to remdesivir.

Main Methods:

  • Literature review of historical background and pharmacology.
  • Analysis of key clinical trials evaluating remdesivir efficacy and safety.
  • Examination of reports on adverse events and patient access.

Main Results:

  • Remdesivir has demonstrated viability as a therapeutic option for COVID-19.
  • Clinical trials provide data on its effectiveness and safety profile.
  • Accessibility and emergency use authorization are critical factors for patient treatment.

Conclusions:

  • Remdesivir is an important antiviral agent for managing COVID-19 in hospitalized patients.
  • Understanding its background, efficacy, and limitations is crucial for clinical application.
  • Ongoing evaluation of accessibility is necessary to ensure equitable patient access.

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.9K

Related Concept Videos

Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
362
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
823
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
122
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
97
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.5K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.2K